Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
A pipeline of unique candidates with the potential to transform the prevention and treatment of cancer and infectious diseases. Our AI-Immunology™ platform enables a high level of scalability, offering the potential to expand our portfolio to the benefit of patients worldwide.
At the forefront of biotechnological innovation, our cutting-edge research is dedicated to advancing vaccine immunotherapies to battle cancer and infectious diseases. With a wide range of multidisciplinary capabilities, our research allows for continuous iterative learning loops which accelerates the development of transformative treatments and significantly enhance the value of our platform.
Since 2021, Evaxion has been listed on the Nasdaq Capital Market exchange (ticker code: EVAX). Here you can find all of the latest Evaxion investor insights: our results, upcoming events and news, important shareholder updates and much more.
We believe collaborating with leading and like-minded partners will create the best-in-class vaccines for patients. Our business model is geared toward a multi-partner approach focused around single or multiple vaccine target discovery, drug design and development agreements
Stay informed with Evaxion’s latest press releases, events, scientific materials, and media resources.
Maxim Growth Summit 2026 span over two days where institutional capital meets the next generation of growth companies. One hundred issuers, eight hundred investors, twelve hundred meetings.
Click here to learn more about the conference.
